4AB.F
AbbVie Inc.
FrankfurtEUREQUITY
Healthcare
DELAYED
Last price
226.90
▲ 1.90 (0.84%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
222.70
Prev close
225.00
Day high
226.90
Day low
222.70
Volume
43
Market cap
$400.96B
P/E (TTM)
75.13
52W range
167.55 – 234.40
Day trading desk
Gap from prior close
-1.02%
Prior close 225.00
VWAP
225.31
+0.71% from price
Relative volume
0.75×
Normal
Session range
1.89%
222.70 – 226.90
Position in range
100%
Near session high
ATR (14D)
3.28
1.44% of price
Prior day high
228.90
PDH
Prior day low
225.00
PDL
Bid / ask spread
—
Quote not published
Session volume
83
Avg 110
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+5.39%
+6.8%
1M
+1.70%
-2.0%
3M
+24.19%
+21.1%
6M
+16.84%
+5.8%
YTD
+16.36%
+4.1%
1Y
+25.78%
+5.8%
3Y
+66.84%
-7.3%
5Y
+151.86%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on 4AB.F open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.94M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 14, 26 | DONOGHOE NICHOLAS Officer |
CONVERSION | 32.71K | $2.58M | Direct |
| Aug 14, 26 | DONOGHOE NICHOLAS Officer |
SELL | 32.71K | $8.18M | Direct |
| May 8, 26 | MEYER MELODY B Director |
STOCK | 1.12K | $0 | Direct |
| May 8, 26 | HART BRETT J Director |
STOCK | 1.12K | $0 | Direct |
| May 8, 26 | BURNSIDE WILLIAM H L Director |
STOCK | 1.12K | $0 | Direct |
| May 8, 26 | RAPP EDWARD J Director |
STOCK | 1.12K | $0 | Direct |
| May 8, 26 | ROBERTS REBECCA B. Director |
STOCK | 1.12K | $0 | Direct |
| May 8, 26 | DAVIS JENNIFER L Director |
STOCK | 1.12K | $0 | Direct |
| May 8, 26 | QUAGGIN SUSAN E Director |
STOCK | 1.12K | $0 | Direct |
| May 8, 26 | AUSTIN ROXANNE SCHUH Director |
STOCK | 1.12K | $0 | Direct |
| May 8, 26 | FREYMAN THOMAS C Director |
STOCK | 1.12K | $0 | Direct |
| May 8, 26 | FALK THOMAS J Director |
STOCK | 1.12K | $0 | Direct |
| May 8, 26 | WADDELL FREDERICK H Director |
STOCK | 1.12K | $0 | Direct |
| Mar 4, 26 | PURDUE DAVID RYAN Officer |
SELL | 5.23K | $1.22M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
DONOGHOE NICHOLAS |
Officer | 74.43K | Conversion of Exercise of derivative security |
FREYMAN THOMAS C |
Director | 135.75K | Stock Award(Grant) |
GONZALEZ RICHARD A |
Director | 386.48K | Stock Gift |
MICHAEL ROBERT A. |
Chief Executive Officer | 215.26K | Stock Award(Grant) |
RAPP EDWARD J |
Director | 45.96K | Stock Award(Grant) |
REENTS SCOTT T. |
Chief Financial Officer | 60.41K | Stock Award(Grant) |
SALEKI-GERHARDT AZITA |
Chief Operating Officer | 220.68K | Stock Award(Grant) |
STEWART JEFFREY RYAN |
Officer | 108.32K | Stock Award(Grant) |
THAKKAR ROOPAL |
Officer | 60.41K | Stock Award(Grant) |
TILTON GLENN FLETCHER |
Director | 51.91K | Stock Award(Grant) |
Fundamentals
Market cap$400.96B
Enterprise value$465.32B
Revenue (TTM)$64.39B
Gross profit$46.87B
EBITDA$30.76B
Net income$6.27B
EPS (TTM)$3.02
Free cash flow$16.87B
Total cash$6.57B
Total debt$70.88B
Book value / share$-2.87
Shares outstanding1.77B
Float1.76B
Short % of float—
Dividend yield2.64%
Beta (5Y)0.28
Valuation & profitability ratios
Trailing P/E75.13
Forward P/E16.24
PEG ratio0.43
Price / sales—
Price / book—
EV / revenue7.23
EV / EBITDA15.13
Gross margin72.79%
Operating margin40.03%
Profit margin9.80%
Return on equity—
Return on assets10.51%
Debt / equity—
Current ratio0.81
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $61.16B | $56.33B | $54.32B | $58.05B | +8.6% |
| Operating revenue | $61.16B | $56.33B | $54.32B | $58.05B | +8.6% |
| Cost of revenue | $18.20B | $16.90B | $20.41B | $17.41B | +7.7% |
| Gross profit | $42.96B | $39.43B | $33.90B | $40.64B | +8.9% |
| Research & development | $9.10B | $12.79B | $7.67B | $6.51B | -28.9% |
| Selling, general & admin | $14.01B | $14.75B | $12.87B | $15.26B | -5.0% |
| Total operating expense | $22.86B | $27.54B | $20.37B | $21.83B | -17.0% |
| Operating income | $20.09B | $11.89B | $13.54B | $18.81B | +68.9% |
| Net interest income | -$2.63B | -$2.16B | -$1.68B | -$2.04B | -21.6% |
| Pre-tax income | $6.60B | $3.72B | $6.25B | $13.48B | +77.5% |
| Tax provision | $2.36B | -$570.00M | $1.38B | $1.63B | +514.7% |
| Net income | $4.23B | $4.28B | $4.86B | $11.84B | -1.2% |
| Net income to common | $4.19B | $4.24B | $4.82B | $11.78B | -1.2% |
| Basic EPS | 2.39 | 2.42 | 2.75 | 6.69 | -1.4% |
| Diluted EPS | 2.36 | 2.39 | 2.72 | 6.63 | -1.3% |
| EBIT | $9.49B | $6.52B | $8.47B | $15.71B | +45.5% |
| EBITDA | $17.63B | $14.91B | $17.17B | $24.17B | +18.2% |
| Basic shares | 1.77B | 1.77B | 1.77B | 1.77B | +0.1% |
| Diluted shares | 1.77B | 1.77B | 1.77B | 1.78B | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $5.23B | $5.52B | $12.81B | $9.20B | -5.3% |
| Cash & short-term investments | $5.26B | $5.55B | $12.82B | $9.23B | -5.4% |
| Accounts receivable | $12.59B | $10.92B | $11.15B | $11.25B | +15.3% |
| Inventory | $4.95B | $4.18B | $4.10B | $3.58B | +18.4% |
| Total current assets | $29.06B | $25.58B | $33.00B | $28.46B | +13.6% |
| Property, plant & equipment | $5.63B | $5.13B | $4.99B | $4.93B | +9.6% |
| Goodwill & intangibles | $88.28B | $95.02B | $87.90B | $99.59B | -7.1% |
| Total assets | $133.96B | $135.16B | $134.71B | $138.81B | -0.9% |
| Total current liabilities | $43.29B | $38.75B | $37.84B | $29.54B | +11.7% |
| Current debt | $8.55B | $6.80B | $7.19B | $4.14B | +25.7% |
| Long-term debt | $58.94B | $60.34B | $52.19B | $59.13B | -2.3% |
| Total debt | $67.50B | $67.14B | $59.38B | $63.27B | +0.5% |
| Total liabilities | $137.19B | $131.80B | $124.31B | $121.52B | +4.1% |
| Retained earnings | -$15.49B | -$7.90B | -$1.00B | $4.78B | -96.1% |
| Shareholder equity | -$3.27B | $3.33B | $10.36B | $17.25B | -198.3% |
| Working capital | -$14.23B | -$13.17B | -$4.84B | -$1.07B | -8.1% |
| Net tangible assets | -$91.55B | -$91.70B | -$77.54B | -$82.34B | +0.2% |
| Shares issued | 1.84B | 1.83B | 1.82B | 1.81B | +0.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $4.23B | $4.29B | $4.87B | $11.85B | -1.2% |
| Depreciation & amortisation | $8.14B | $8.39B | $8.70B | $8.47B | -2.9% |
| Stock-based compensation | $955.00M | $911.00M | $747.00M | $671.00M | +4.8% |
| Change in working capital | -$2.36B | -$2.78B | $2.81B | -$94.00M | +15.1% |
| Operating cash flow | $19.03B | $18.81B | $22.84B | $24.94B | +1.2% |
| Capital expenditure | -$1.21B | -$974.00M | -$777.00M | -$695.00M | -24.6% |
| Investing cash flow | -$6.64B | -$20.82B | -$2.01B | -$623.00M | +68.1% |
| Share buybacks | -$980.00M | -$1.71B | -$1.97B | -$1.49B | +42.6% |
| Dividends paid | -$11.66B | -$11.03B | -$10.54B | -$10.04B | -5.7% |
| Financing cash flow | -$12.72B | -$5.21B | -$17.22B | -$24.80B | -144.2% |
| Free cash flow | $17.82B | $17.83B | $22.06B | $24.25B | -0.1% |
| End cash position | $5.23B | $5.52B | $12.81B | $9.20B | -5.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $16.99B | $15.00B | $16.62B | $15.78B | $15.42B | — | +13.3% |
| Operating revenue | $16.99B | $15.00B | $16.62B | $15.78B | $15.42B | — | +13.3% |
| Cost of revenue | $4.29B | $4.22B | $4.55B | $5.30B | $4.35B | — | +1.7% |
| Gross profit | $12.70B | $10.78B | $12.07B | $10.47B | $11.08B | — | +17.8% |
| Research & development | $2.34B | $2.47B | $2.58B | $2.32B | $2.13B | — | -5.2% |
| Selling, general & admin | $3.63B | $3.58B | $3.90B | $3.57B | $3.25B | — | +1.5% |
| Total operating expense | $5.98B | $6.05B | $6.26B | $5.89B | $5.36B | — | -1.2% |
| Operating income | $6.72B | $4.73B | $5.81B | $4.58B | $5.72B | — | +42.0% |
| Net interest income | -$679.00M | -$645.00M | -$655.00M | -$667.00M | -$678.00M | — | -5.3% |
| Pre-tax income | $4.28B | $1.04B | $2.67B | $714.00M | $1.55B | — | +311.7% |
| Tax provision | $662.00M | $342.00M | $853.00M | $526.00M | $613.00M | — | +93.6% |
| Net income | $3.61B | $695.00M | $1.82B | $186.00M | $938.00M | — | +419.9% |
| Net income to common | $3.60B | $685.00M | $1.81B | $176.00M | $928.00M | — | +425.7% |
| Basic EPS | 2.04 | 0.39 | 1.03 | 0.11 | 0.53 | — | +419.8% |
| Diluted EPS | 2.03 | 0.39 | 1.02 | — | 0.52 | 0.72 | +420.5% |
| EBIT | $5.02B | $1.76B | $3.38B | $1.45B | $2.29B | — | +186.1% |
| EBITDA | $6.91B | $3.69B | $5.37B | $3.52B | $4.34B | — | +87.1% |
| Basic shares | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | — | +0.0% |
| Diluted shares | 1.77B | 1.77B | 1.77B | — | 1.77B | 1.77B | -0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.57B | $9.39B | $5.23B | $5.63B | $6.47B | -30.1% |
| Cash & short-term investments | $6.57B | $9.39B | $5.26B | $5.67B | $6.47B | -30.1% |
| Accounts receivable | $13.82B | $12.48B | $12.59B | $12.77B | $12.64B | +10.8% |
| Inventory | $5.13B | $5.05B | $4.95B | $4.94B | $4.96B | +1.5% |
| Total current assets | $33.67B | $33.53B | $29.06B | $28.54B | $29.26B | +0.4% |
| Property, plant & equipment | $5.80B | $5.69B | $5.63B | $5.48B | $5.28B | +1.9% |
| Goodwill & intangibles | $84.66B | $86.44B | $88.28B | $89.94B | $92.67B | -2.1% |
| Total assets | $135.12B | $136.46B | $133.96B | $133.90B | $137.18B | -1.0% |
| Total current liabilities | $41.64B | $42.10B | $43.29B | $39.39B | $39.77B | -1.1% |
| Current debt | $8.34B | $8.33B | $8.55B | $5.77B | $7.52B | +0.2% |
| Long-term debt | $62.48B | $64.53B | $58.94B | $62.97B | $62.96B | -3.2% |
| Total debt | $70.82B | $72.86B | $67.50B | $68.74B | $70.48B | -2.8% |
| Total liabilities | $141.00B | $143.07B | $137.19B | $136.50B | $137.32B | -1.4% |
| Retained earnings | -$17.33B | -$17.87B | -$15.49B | -$14.23B | -$11.50B | +3.0% |
| Shareholder equity | -$5.93B | -$6.66B | -$3.27B | -$2.64B | -$183.00M | +10.8% |
| Working capital | -$7.97B | -$8.57B | -$14.23B | -$10.85B | -$10.51B | +7.0% |
| Net tangible assets | -$90.59B | -$93.10B | -$91.55B | -$92.58B | -$92.85B | +2.7% |
| Shares issued | 1.77B | 1.84B | 1.84B | 1.84B | 1.84B | -4.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $3.62B | $697.00M | $1.81B | $188.00M | $941.00M | +418.8% |
| Depreciation & amortisation | $1.88B | $1.94B | $1.99B | $2.06B | $2.05B | -2.7% |
| Stock-based compensation | $166.00M | $444.00M | $157.00M | $209.00M | $179.00M | -62.6% |
| Change in working capital | -$2.72B | -$1.92B | -$473.00M | $1.25B | -$562.00M | -41.6% |
| Operating cash flow | $3.44B | $3.83B | $5.22B | $7.02B | $5.15B | -10.3% |
| Capital expenditure | -$322.00M | -$265.00M | -$329.00M | -$381.00M | -$269.00M | -21.5% |
| Investing cash flow | -$1.20B | -$574.00M | -$1.46B | -$3.26B | -$1.18B | -108.5% |
| Share buybacks | -$9.00M | -$1.49B | -$3.00M | -$4.00M | -$12.00M | +99.4% |
| Dividends paid | -$3.07B | -$3.09B | -$2.91B | -$2.91B | -$2.91B | +0.5% |
| Financing cash flow | -$5.05B | $919.00M | -$4.17B | -$4.59B | -$2.71B | -649.9% |
| Free cash flow | $3.11B | $3.56B | $4.89B | $6.64B | $4.88B | -12.6% |
| End cash position | $6.57B | $9.39B | $5.23B | $5.63B | $6.47B | -30.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $17.31B | +9.8% |
| Next quarter | — | — | $18.31B | +10.2% |
| Current year | — | — | $67.58B | +10.5% |
| Next year | — | — | $73.52B | +8.8% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.11%
Held by institutions77.43%
Institutions holding5.24K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
218.65
+3.77% from price
SMA 20
219.29
+3.47% from price
SMA 50
216.51
+4.80% from price
SMA 100
198.78
+14.15% from price
SMA 200
195.08
+16.31% from price
EMA 12
220.15
+3.07% from price
EMA 26
218.57
+3.81% from price
EMA 50
214.02
+6.02% from price
RSI (14)
62.0
Neutral
MACD (12,26,9)
1.57
Hist 0.89
ATR (14)
3.28
1.44% of price
Realised vol 30D
28.7%
Annualised
Bollinger upper
233.57
20, 2σ
Bollinger lower
205.01
20, 2σ
50 / 200 cross
Golden
216.51 vs 195.08
Trend bias
Above 200
+16.31%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.42
Less volatile than market
Correlation to SPY
-0.18
Largely independent
Realised vol 30D
28.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-18.7%
Peak to trough
Max drawdown 5Y
-26.2%
Peak to trough
ATR 14
3.28
1.44% of price
Beta (reported)
0.28
5Y monthly, from filing
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 17, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Aug 13, 26 | Wolfe Research | UPGRADE | Peer Perform | Outperform |
| Aug 11, 26 | BNP Paribas | MAINTAINED | Neutral | Neutral |
| Aug 10, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Aug 4, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 3, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Aug 3, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Jul 29, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 22, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jul 15, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Jul 13, 26 | UBS | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate$6.00 / yr
Forward yield2.64%
5-year avg yield3.60%
Payout ratio190.40%
Ex-dividend dateJul 15, 2026
Next pay date—
Last split—
Split date—
Headlines
Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery?
Insider Monkey · 11m ago
Dow Jones Futures Fall With Tariffs In Focus; Nvidia, Warsh Ahead
Investor's Business Daily · 14m ago
Syria says Israel talks addressed de-escalation, staying out of Israel-Turkey tensions
AFP · 17m ago
FIA Hails Success of Landmark INDYCAR Freedom 250 Grand Prix as Motorsport Takes Centre Stage in Washington D.C.
Business Wire · 21m ago
The next big oil trade may have nothing to do with oil stocks
TheStreet · 21m ago
First lady Melania Trump says she 'loved' racing as a child
USA TODAY · 22m ago
Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable?
Insider Monkey · 22m ago
Crowder College offering training courses in August, September
The Joplin Globe, Mo. · 23m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.